Trending Topics in Gastroenterology | GastroAGI

Immune Modulators in HBV therapy

Immune modulators in HBV therapy aim to restore or augment the host immune response against the hepatitis B virus (HBV). Chronic HBV infection is often characterized by immune tolerance and exhaustion of HBV-specific immune cells. Immune modulators are being developed to overcome these challenges and enhance the immune system's ability to control or eliminate the virus. Below is a detailed overview of the key immune modulators used in HBV therapy: --- ### **1. Innate Immune Agonists** These agents target the innate immune system, the body's first line of defense, to stimulate antiviral responses. #### **A. Toll-Like Receptor (TLR) Agonists** - **Example:** Vesatolimod (GS-9688) - **Mechanism of Action:** Vesatolimod is a TLR8 agonist that activates innate immune pathways, including cytokine production and the stimulation of antiviral immune responses. TLR agonists can enhance the activity of natural killer (NK) cells and dendritic cells, which play crucial roles in controlling HBV infection. - **Goal:** Promote antiviral immunity and reduce HBV replication. #### **B. RIG-I Agonists** - **Example:** SB-9200 - **Mechanism of Action:** SB-9200 targets RIG-I (Retinoic Acid-Inducible Gene I), a cytoplasmic receptor involved in detecting viral RNA. Activation of RIG-I leads to the production of interferons and other antiviral molecules, enhancing the immune response against HBV. - **Goal:** Stimulate innate antiviral immunity to suppress HBV replication. --- ### **2. Checkpoint Inhibitors** Checkpoint inhibitors are designed to overcome immune exhaustion by blocking inhibitory signals that suppress T-cell activity. #### **A. Examples** - **Nivolumab:** A PD-1 (Programmed Death-1) inhibitor that reactivates exhausted T-cells, enabling them to respond more effectively to HBV infection. - **ASC22 (Envafolimab):** A PD-L1 (Programmed Death-Ligand 1) inhibitor that works similarly to Nivolumab by reinvigorating HBV-specific T-cell responses. #### **B. Mechanism of Action** Checkpoint inhibitors target immune checkpoints such as PD-1/PD-L1 pathways, which are upregulated in chronic HBV infection and contribute to T-cell exhaustion. By blocking these pathways, checkpoint inhibitors restore T-cell function and enhance antiviral immunity. #### **C. Challenges** - **Modest HBsAg Decline:** While checkpoint inhibitors can improve immune responses, their effect on reducing HBV surface antigen (HBsAg) levels has been modest. - **Risk of Autoimmunity:** By reactivating immune cells, checkpoint inhibitors may inadvertently trigger autoimmune responses, posing potential safety concerns. --- ### **3. Therapeutic Vaccines** Therapeutic vaccines aim to break immune tolerance and enhance HBV-specific immune responses, particularly T-cell activity. #### **A. Examples** - **GS-4774:** A yeast-based therapeutic vaccine designed to stimulate HBV-specific T-cell responses. - **INO-1800:** A DNA-based vaccine targeting HBV antigens to elicit strong cellular and humoral immune responses. - **NASVAC:** A nasal vaccine combining HBV core and surface antigens to boost immunity. - **BRII-179:** A therapeutic vaccine developed to enhance HBV-specific T-cell responses. #### **B. Mechanism of Action** Therapeutic vaccines work by presenting HBV antigens to the immune system in a way that stimulates HBV-specific T-cells. These vaccines aim to overcome immune tolerance and restore the ability of the immune system to recognize and attack HBV-infected cells. #### **C. Goal** The primary goal of therapeutic vaccines is to induce a robust and sustained immune response that can help control or eliminate HBV infection. --- ### **Overall Goal of Immune Modulators in HBV Therapy** The ultimate aim of immune modulators is to restore or augment the host immune response to HBV. This includes: - Breaking immune tolerance. - Reinvigorating exhausted T-cells. - Enhancing innate and adaptive immune responses. - Reducing viral replication and HBsAg levels. Immune modulators represent a promising avenue for achieving functional cure in HBV patients, particularly when used in combination with other antiviral therapies. However, challenges such as safety concerns, modest efficacy, and variability in patient responses remain areas of active research.

Acute Obstructive Suppurative Pancreatic Ductitis

**Acute Obstructive Suppurative Pancreatic Ductitis (AOSPD)** is a rare but distinct clinical condition characterized by infection and obstruction of the pancreatic duct, leading to suppurative (pus-forming) inflammation. Below is a detailed overview based on the provided context: --- ### **Definition and Overview** - **Acute Obstructive Suppurative Pancreatic Ductitis (AOSPD)** refers to an acute infectious and obstructive condition affecting the pancreatic duct, often associated with chronic pancreatitis and prior pancreaticobiliary interventions. - It is distinct from other pancreatic conditions such as acute-on-chronic pancreatitis, with specific clinical, laboratory, and imaging findings. --- ### **Epidemiology** - AOSPD primarily affects **middle-aged and elderly men**. - It is strongly associated with predisposing factors such as: - **Chronic pancreatitis** - **Alcohol use** - **Smoking** - **Pancreatic ductal stones** - **History of pancreaticobiliary interventions** --- ### **Clinical Presentation** The main symptoms of AOSPD include: 1. **Abdominal Pain**: A prominent symptom, often severe and localized. 2. **Fever**: Suggestive of an infectious process. --- ### **Laboratory Findings** - Elevated **inflammatory markers** such as: - White blood cell count (WBC) - C-reactive protein (CRP) - Erythrocyte sedimentation rate (ESR) - These findings reflect the acute inflammatory and infectious nature of the condition. --- ### **Imaging Features** - Imaging studies (e.g., CT, MRI, or ERCP) typically reveal: - **Ductal dilatation**: Indicative of obstruction within the pancreatic duct. - Additional findings may include the presence of stones or strictures. --- ### **Microbiology** - **Pancreatic juice cultures** are often positive, confirming the infectious nature of the disease. - The specific organisms isolated may vary, but the presence of pathogens in pancreatic juice underscores the suppurative (infectious) component of the condition. --- ### **Risk Factors** Compared to acute-on-chronic pancreatitis, AOSPD has stronger associations with: - **Alcohol consumption** - **Smoking** - **Pancreatic ductal stones** --- ### **Management** 1. **Endoscopic Interventions**: - The **mainstay of treatment**, aimed at relieving obstruction and draining the infected pancreatic duct. - Techniques may include endoscopic retrograde cholangiopancreatography (ERCP) with stenting or stone removal. 2. **Surgery**: - Reserved for cases where endoscopic management fails or complications arise. - May involve procedures to address underlying structural abnormalities. 3. **Antibiotics**: - Used in select cases to manage the infectious component of the disease. - Empiric antibiotic therapy should be guided by culture results when available. --- ### **Prognosis** - With **timely diagnosis** and **appropriate management**, the short-term outcomes of AOSPD are generally favorable. - Delayed or inadequate treatment, however, may lead to complications such as abscess formation, sepsis, or progression of chronic pancreatitis. --- ### **Conclusion** AOSPD is a rare but important clinical entity that requires a high index of suspicion, especially in patients with chronic pancreatitis and a history of pancreaticobiliary interventions. The combination of clinical, laboratory, and imaging findings facilitates diagnosis, while endoscopic interventions play a central role in management. Early recognition and treatment are crucial to achieving positive outcomes.

Endohepatology – Current View

### **Endohepatology – Current View** Endohepatology is an emerging and innovative field that integrates endoscopic ultrasound (EUS)-based diagnostic and therapeutic interventions into hepatology practice. This approach is revolutionizing the management of liver diseases by expanding the scope of traditional endoscopy beyond procedures like variceal ligation. By combining hepatology and advanced endoscopic techniques, endohepatology is streamlining care, improving diagnostic accuracy, and offering minimally invasive therapeutic options for a wide range of liver-related conditions. Below is a detailed overview of the current state of endohepatology: --- ### **Key Components and Applications** #### **1. Streamlined Care** - **Efficiency:** Endohepatology allows for multiple diagnostic and therapeutic procedures to be performed in a single session, reducing the need for multiple hospital visits. Examples include: - Variceal surveillance - EUS-guided liver stiffness assessment - Targeted liver biopsy - **Patient Satisfaction:** This streamlined approach enhances patient convenience and reduces procedural burden. #### **2. EUS-Guided Liver Biopsy (EUS-LBx)** - **Minimally Invasive Alternative:** EUS-LBx is gaining popularity over traditional percutaneous liver biopsy due to its ability to sample both liver lobes under Doppler guidance, minimizing the risk of vascular injury. - **Biopsy Quality:** - Optimal biopsy cores require a length of ≥20 mm and ≥11 complete portal tracts. - Studies show that 19G needles and wet suction techniques provide better adequacy compared to smaller or dry needles. - **Diagnostic Accuracy:** - Meta-analyses report diagnostic adequacy rates of ~88% for EUS-LBx compared to ~98% for percutaneous biopsy. However, newer techniques are narrowing this gap. #### **3. Targeted Lesion Biopsy** - **Precision:** EUS enables targeted sampling of focal liver lesions, particularly those located in challenging areas like the left lobe. - **Sensitivity:** High sensitivity for detecting hepatocellular carcinoma (HCC) and liver metastases, making it a valuable tool for oncological diagnosis. #### **4. Variceal Management** - **EUS-Guided Coil and Glue Injection:** - Safer and more effective therapy for gastric varices compared to direct injection. - Reduces rebleeding rates and procedural risks. - **Clinical Success of Coil Therapy:** - Large multicenter studies report >90% obliteration of gastric varices and <5% post-therapy bleeding. - Outperforms cyanoacrylate injection alone. - **Esophageal Variceal Bleeding:** - For refractory cases, EUS and self-expanding metal stents (SEMS) are emerging alternatives to balloon tamponade, offering better hemostasis and fewer complications. #### **5. Transplant Applications** - **Post-Transplant Support:** Endoscopy plays a crucial role in managing liver transplant patients through: - ERCP for biliary strictures and leaks. - EUS for post-transplant liver biopsies. - **Streamlined Diagnosis:** Same-session ERCP and EUS biopsy streamline evaluations, reducing time to diagnosis and treatment. #### **6. EUS in Ascites** - **Enhanced Detection:** EUS detects ascites more sensitively than imaging modalities like ultrasound or CT. - **Fluid Aspiration:** Enables cytological and infection testing, particularly valuable in cases where malignancy is suspected. #### **7. EUS for Liver Abscess** - **Drainage:** In select cases, such as left lobe abscesses, EUS-guided drainage offers: - Faster symptom resolution - Fewer complications - Shorter hospital stays compared to percutaneous drainage. #### **8. EUS-Guided Elastography (EUS-SWE)** - **Advanced Fibrosis Staging:** Measures liver stiffness more accurately in patients with obesity or ascites, outperforming traditional methods like FibroScan or FIB-4. - **Clinical Impact:** Provides superior staging of liver fibrosis, aiding in disease management. #### **9. Portal Venous Sampling** - **Prognostic Insights:** EUS enables portal vein sampling to analyze circulating tumor cells (CTCs), offering valuable prognostic information in gastrointestinal cancers. - **Research Potential:** May provide insights into microbiome and metabolomics for future therapeutic applications. #### **10. Experimental Tumor Therapies** - **Innovative Approaches:** EUS-guided delivery of experimental therapies for HCC and metastases is under investigation, including: - Ethanol injection - Chemotherapy microbeads - Radiofrequency ablation - Gene therapy #### **11. Portal Pressure Gradient (EUS-PPG)** - **Direct Measurement:** EUS-PPG directly measures portal hypertension and demonstrates strong correlation with the gold standard hepatic venous pressure gradient (HVPG). - **Technical Success:** ~95% success rate with minimal adverse events. #### **12. EUS Portosystemic Shunts** - **Animal Studies:** Feasibility of creating portosystemic shunts with lumen-apposing stents mimicking transjugular intrahepatic portosystemic shunt (TIPS). - **Challenges:** Issues like thrombosis need to be resolved before clinical application. #### **13. Endobariatrics Integration** - **MASLD (Metabolic Associated Steatotic Liver Disease):** Endoscopic bariatric therapies like ESG (endoscopic sleeve gastroplasty) and TORe (transoral outlet reduction) show: - Significant weight loss - Reduced fibrosis scores - Improved portal pressures - **Combination Therapies:** ESG combined with GLP-1 agonists yields greater weight loss and fibrosis reduction compared to endoscopy alone, highlighting synergy between endoscopic and pharmacologic approaches. --- ### **Future Outlook** Endohepatology is rapidly evolving as a multidisciplinary field with immense potential to transform hepatology practice. While several interventions, such as coil therapy for varices and EUS elastography, have already demonstrated clinical impact, others remain experimental and require further validation. Key areas of ongoing research and development include: - Refining techniques for EUS-guided liver biopsy to match or exceed the diagnostic adequacy of percutaneous biopsy. - Advancing experimental tumor therapies for HCC and metastases. - Addressing technical challenges in creating EUS-guided portosystemic shunts. - Expanding the integration of endobariatrics into MASLD management. As technology and research progress, endohepatology is expected to become a cornerstone of liver disease management, offering minimally invasive, highly effective solutions for diagnosis and treatment.

Refractory GERD-induced chronic cough and vonoprazan

Refractory gastroesophageal reflux disease (GERD)-induced chronic cough (GERC) refers to a persistent cough caused by acid reflux that does not respond adequately to standard treatment with proton-pump inhibitors (PPIs). Chronic cough associated with GERD can significantly impact a patient’s quality of life, and finding effective treatment options for refractory cases is a clinical challenge. ### Key Points about Refractory GERD-Induced Chronic Cough and Vonoprazan: #### 1. **Refractory GERD-Induced Chronic Cough:** - **Definition:** Chronic cough lasting more than 8 weeks, attributed to GERD, that does not improve with standard PPI therapy. - **Pathophysiology:** GERD-induced cough may occur due to microaspiration of stomach contents into the airways or a vagally mediated reflex triggered by esophageal acid exposure. - **Challenges with PPIs:** - PPIs work by inhibiting the proton pump in gastric parietal cells, reducing stomach acid production. - Some patients experience incomplete acid suppression with PPIs, leading to persistent symptoms, including chronic cough. - Variability in PPI response could be due to differences in metabolism, adherence, or acid breakthrough. #### 2. **Vonoprazan as a New Treatment Option:** - **Mechanism of Action:** - Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion by targeting the potassium-binding site of the proton pump. - It provides more rapid, potent, and sustained acid suppression compared to PPIs. - **Advantages Over PPIs:** - Faster onset of action. - Stronger and more consistent acid suppression, including during the nighttime, when acid breakthrough is common with PPIs. - Potential to improve symptoms in patients with refractory GERD and associated chronic cough. #### 3. **Case Series Evidence:** - In a small case series, vonoprazan was tested in three patients with refractory GERC who had failed to respond to 8 weeks of PPI therapy. - **Outcomes:** - All three patients experienced complete resolution of their chronic cough after switching to vonoprazan. - This suggests that vonoprazan may be an effective alternative for patients with refractory GERC. #### 4. **Clinical Implications:** - Vonoprazan offers a promising therapeutic option for patients with GERD-induced chronic cough who do not respond to standard PPI therapy. - It may be especially beneficial in cases where stronger and more consistent acid suppression is required. - Given the limited data, larger studies and clinical trials are needed to confirm vonoprazan’s efficacy and safety in this patient population. #### 5. **Considerations for Practice:** - **Diagnosis:** Accurate diagnosis of GERD-induced chronic cough is essential to ensure appropriate treatment. This may involve pH monitoring, impedance testing, or response to therapeutic trials. - **Treatment Algorithm:** - For patients with refractory symptoms, switching from PPIs to vonoprazan may be a reasonable strategy. - Lifestyle modifications (e.g., weight management, dietary changes, head-of-bed elevation) should also be emphasized. - **Monitoring:** Patients should be monitored for symptom resolution and potential side effects of vonoprazan. ### Conclusion: Vonoprazan represents a promising alternative for managing refractory GERD-induced chronic cough, particularly in cases where PPIs fail to provide adequate symptom control. While the initial evidence is encouraging, further research is needed to establish its role in broader clinical practice.